CatalYm appoints business chief Dr Phil L’Huillier
MUNICH, Germany, Could 4, 2021 (GLOBE NEWSWIRE) – CatalYm GmbH, a biopharmaceutical firm creating novel most cancers immunotherapies, right this moment introduced the appointment of Dr. Phil L’Huillier as CEO, efficient Could 17, 2021. The Dr Phil L’Huillier has greater than 20 years of expertise in administration positions within the pharmaceutical and biotechnology industries, with an distinctive monitor file of success within the industrial growth of corporations and partnerships. His background displays a global profession in enterprise, science and academia.
Dr Phil L’Huillier joins CatalYm as Head of European Innovation Hub and Enterprise Improvement at MSD (referred to as Merck & Co. in North America). On this position, he was an energetic member of MSD International Enterprise Improvement and Licensing Management and led a crew of scientific and enterprise growth professionals who targeted on the identification, analysis and growth of recent sciences rising from academia, biotechnology and peer-pharma. His crew has additionally carried out quite a few collaborations, licenses and main pharmaceutical acquisitions masking the therapeutic areas of MSD.
Dr. L’Huillier labored for a decade as CEO and Board Member of Most cancers Analysis Expertise (CRT), a number one oncology-focused expertise commercialization and drug discovery firm, the place he was accountable for the event, commercialization and licensing of quite a few packages, beginning with discovery. within the early scientific levels. He concurrently performed key roles within the formation of a lot of biotech corporations and was a non-executive director of Achilles Therapeutic Artios Pharma, BliNK Therapeutics, PsiOxus Therapeutics, Revitope and Senectus Therapeutics, overseeing and supporting fundraising actions. and industrial. Previous to CRT, Dr. L’Huillier led international licensing and enterprise growth at BioFocus Discovery, an built-in early-stage drug discovery firm registered with AIM and which was acquired by Galapagos. Earlier than becoming a member of the industrial business, he additionally led a analysis crew for a interval of 5 years after his doctoral and post-doctoral coaching. Dr L’Huillier holds a PhD in Mobile and Molecular Biology from the College of Auckland, New Zealand, in addition to an MBA.
“It’s a actual pleasure to welcome Dr Phil L’Huillier as the brand new CEO of CatalYm. Phil is a really skilled pharmaceutical government, famend for his strategic experience, administration expertise and know-how in biotech finance and BD transactions, ”stated Dr John Haurum, Chairman of the Supervisory Board of CatalYm. “Having joined CatalYm earlier this yr and now with Phil as CEO, we’re effectively positioned to execute CatalYm’s enterprise technique. Moreover, with Phil on the helm, we now have a powerful crew in place to steer the enterprise via the following levels of growth and produce our extremely revolutionary anti-GDF-15 most cancers immunotherapy to profitable scientific proof of idea.
Dr. Phil L’Huillier, CEO-designate of CatalYm, stated: “I’m delighted to hitch and lead CatalYm in these thrilling instances. This firm has vital potential to reshape the most cancers immunotherapy house because of the brand new mechanism presently being examined in early scientific growth. I look ahead to working with the very skilled and proficient CatalYm crew and board of administrators to create new remedy choices for sufferers presently unresponsive to checkpoint inhibitor remedy. The design of the present scientific trial is sensible and has the potential to pave the best way for revolutionary mixture therapies in sufferers with excessive medical want.
CatalYm is a biopharmaceutical firm creating novel anti-cancer immunotherapies concentrating on progress and differentiation issue 15 (GDF-15). Along with its established position in cachexia, GDF-15 has been related to immunosuppression in tissues and tumors and a quickly rising physique of literature helps the idea that GDF-15 is a significant T cell repellent. CatalYm goals to neutralize GDF-15 to make tumors “chilly” “sizzling” and thus considerably enhance the efficacy of established immunotherapy similar to anti-PD1 / -PD-L1 checkpoint inhibitors. The Firm’s lead product candidate, CTL-002, a GDF-15 neutralizing antibody, is presently beneath scientific analysis in a two-part, open-label, multicenter Section I scientific trial (GDFATHER trial).
The corporate was based in 2016 as a spin-off of the Julius-Maximilians College in Würzburg on the premise of the revolutionary analysis work of Prof. Dr. Joerg Wischhusen. CatalYm is led by a seasoned administration crew with vital expertise in IO drug growth in addition to buying and selling expertise and supported by worldwide enterprise capital traders e.g. Forbion and BioGeneration Ventures, Vesalius Biocapital III, Novartis Enterprise Fund, Wachstumsfonds Bayern and coparion. CatalYm has acquired monetary assist from the EIF via the EIB-EIF co-investment mechanism, supported by the European Union via the European Fund for Strategic Investments (EFSI).
Am Klopferspitz 19
82152 Martinsried, Planegg
MC Companies AG
Katja Arnold, Julia von Hummel, Shaun Brown
T: +49 (0) 89 2102280